ArticleNature communications2026
Discovery of antimicrobial peptides targeting Acinetobacter baumannii via a pre-trained and fine-tuned few-shot learning-based pipeline.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Combating Antibacterial Resistance: The Integrative Role of Artificial Intelligence in Bio-Based Product Development.Antibiotics (Basel, Switzerland) · 2026Review
- Machine learning-driven discovery of antimicrobial peptides againstFrontiers in pharmacology · 2026Article
- AI-Driven Antimicrobial Peptide Discovery: Mining and Generation.Accounts of chemical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acinetobacter baumannii, a robust Gram-negative bacterium known for causing nosocomial infections, exhibiting multidrug resistance, and lacking antimicrobial peptides that target it, remains hard to treat. Here, we report a few-shot learning pipeline integrating classification, ranking, and regression modules. Each module is trained via a few-shot learning strategy involving pre-training and multiple fine-tuning steps, incorporating similar and true data for fine-tuning, to identify potent AMPs against Acinetobacter baumannii. This pipeline effectively scans complete libraries of hexapeptides, heptapeptides, and octapeptides (encompassing tens of billions of candidates) despite the extreme scarcity of training data. Results show it discovers AMPs active against Acinetobacter baumannii and Candida albicans, with low off-target toxicity and negligible drug resistance susceptibility. Additionally, EME7(7) controls Acinetobacter baumannii pneumonia in mice without kidney injury, a contrast to the observed effects of polymyxin B. This work provides a paradigm for addressing challenges of limited data availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.